Association Between Persistence with Oral Atypical Antipsychotic Medications and Hospital and Emergency Department Utilization in Medicaid Patients with Schizophrenia

References

• Menditto E, Cahir C, Malo S, et al. Persistence as a robust indicator of medication adherence-related quality and performance. Int J Environ Res Public Health. 2021;18(9):4872. doi:10.3390/ijerph18094872
   PubMed Web of Science ®Google Scholar
• Hartman L, Lems WF, Boers M. Outcome measures for adherence data from a medication event monitoring system: a literature review. J Clin Pharm Ther. 2019;44(1):1–5. doi:10.1111/jcpt.12757
   PubMed Web of Science ®Google Scholar
• Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469–481. doi:10.1007/s40263-021-00815-y
   PubMed Web of Science ®Google Scholar
• Semahegn A, Torpey K, Manu A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systemic review and meta-analysis. Syst Rev. 2020;9(1):17. doi:10.1186/s13643-020-1274-3
   PubMed Web of Science ®Google Scholar
• García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenia patients: a systematic review. J Clin Psychopharmacol. 2016;36(4):355–371. doi:10.1097/JCP.0000000000000523
   PubMed Web of Science ®Google Scholar
• Sendt K-V, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1–2):14–30. doi:10.1016/j.psychres.2014.11.002
   PubMed Web of Science ®Google Scholar
• Shah A, Xie L, Kariburyo F, et al. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Ther. 2018;35(11):1994–2014. doi:10.1007/s12325-018-0786-x
   PubMed Web of Science ®Google Scholar
• Pesa JA, Doshi D, Wang L, et al. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Curr Med Res Opin. 2017;33(4):723–731. doi:10.1080/03007995.2016.1278202
   PubMed Web of Science ®Google Scholar
• Richards K, Johnsrud M, Zacker C, Sasané R. One-year medication treatment patterns, healthcare resource utilization, and expenditures for Medicaid patients with schizophrenia starting oral atypical antipsychotic medication. Adm Policy Ment Health. 2023;1–10. doi:10.1007/s10488-023-01327-1
   Web of Science ®Google Scholar
• Pilon D, Joshi K, Tandon N, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence. 2017;11:619–629. doi:10.2147/PPA.S127623
   PubMed Web of Science ®Google Scholar
• Cahaya N, Kristina SA, Widayanti AW, Green J. Interventions to improve medication adherence in people with schizophrenia: a systematic review. Patient Prefer Adherence. 2022;16:2431–2449. doi:10.2147/PPA.S378951
   PubMed Web of Science ®Google Scholar
• Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016;51(2):211–219. doi:10.1177/0091217416636601
   PubMed Web of Science ®Google Scholar
• Panish J, Karve S, Candrilli SD, Dirani R. Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. J Pharm Health Serv Res. 2013;4(1):29–39. doi:10.1111/jphs.12004
   PubMedGoogle Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127–134. doi:10.1080/13696998.2017.1379412
   PubMed Web of Science ®Google Scholar
• Geissler KH, Ericson KM, Simon GE, et al. Differences in insurance coverage for individuals with schizophrenia after implementation of the Patient Protection and Affordable Care Act. JAMA. 2023;80(3):278–279. doi:10.1001/jamapsychiatry.2022.4628
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adher. 2013;7:275–284. doi:10.2147/PPA.S41609
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ni W. Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacotherapy. 2015;35(9):813–822. doi:10.1002/phar.1634
   PubMed Web of Science ®Google Scholar
• Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–468. doi:10.2147/PPA.S124658
   PubMed Web of Science ®Google Scholar
• Joseph B, Narayanaswamy JC, Venkatasubramanian G. Insight in schizophrenia: relationship to positive, negative and neurocognitive dimensions. Indian J Psychol Med. 2015;37(1):5–11. doi:10.4103/0253-7176.150797
   PubMedGoogle Scholar
• Du Y, Chen L, X-S L, et al. Metabolomic identification of exosome-derived biomarkers for schizophrenia: a large multicenter study. Schizophr Bull. 2021;47(3):615–623. doi:10.1093/schbul/sbaa166
   PubMed Web of Science ®Google Scholar